140 related articles for article (PubMed ID: 9817268)
1. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer.
Cooper BW; Moss TJ; Ross AA; Ybanez J; Lazarus HM
J Clin Oncol; 1998 Nov; 16(11):3509-17. PubMed ID: 9817268
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
[TBL] [Abstract][Full Text] [Related]
3. Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.
Stadtmauer EA; Tsai DE; Sickles CJ; Mick R; Luger SM; Porter DL; Mangan PA; Schuchter LM; Schuster SJ; Loh EY; Magee DA; Sachs RA; Wall ME; Moore J; Buzby GP; Zaleta E; Kamoun M; Silberstein LE
Med Oncol; 1999 Dec; 16(4):279-88. PubMed ID: 10618691
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance.
Pecora AL; Lazarus HM; Jennis AA; Preti RA; Goldberg SL; Rowley SD; Cantwell S; Cooper BW; Copelan EA; Herzig RH; Meagher R; Kennedy MJ; Akard LR; Jansen J; Ross A; Prilutskaya M; Glassco J; Kahn D; Moss TJ
Biol Blood Marrow Transplant; 2002; 8(10):536-43. PubMed ID: 12434948
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.
Ross AA; Miller GW; Moss TJ; Kahn DG; Warner NE; Sweet DL; Louie KG; Schneidermann E; Pecora AL; Meagher RC
Bone Marrow Transplant; 1995 Jun; 15(6):929-33. PubMed ID: 7581093
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.
Klein JL; Hamm C; Dansey RD; Karanes C; Abella E; Cassells L; Peters WP; Baynes RD
Bone Marrow Transplant; 2001 Dec; 28(11):1023-9. PubMed ID: 11781611
[TBL] [Abstract][Full Text] [Related]
7. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor.
Passos-Coelho JL; Ross AA; Kahn DJ; Moss TJ; Davis JM; Huelskamp AM; Noga SJ; Davidson NE; Kennedy MJ
J Clin Oncol; 1996 Sep; 14(9):2569-75. PubMed ID: 8823337
[TBL] [Abstract][Full Text] [Related]
8. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.
Brockstein BE; Ross AA; Moss TJ; Kahn DG; Hollingsworth K; Williams SF
J Hematother; 1996 Dec; 5(6):617-24. PubMed ID: 9117250
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support.
Franklin WA; Shpall EJ; Archer P; Johnston CS; Garza-Williams S; Hami L; Bitter MA; Bast RC; Jones RB
Breast Cancer Res Treat; 1996; 41(1):1-13. PubMed ID: 8932871
[TBL] [Abstract][Full Text] [Related]
11. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation support in a patient with breast cancer metastasis to bone marrow: immunocytochemical monitoring of cancer-cell contamination].
Uno H; Fujita M; Hino N; Nakagawa H; Miyagawa H; Aoki J; Taniyama K; Sasaki N
Rinsho Ketsueki; 1999 Jul; 40(7):556-62. PubMed ID: 10483138
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.
Shpall EJ; Jones RB; Bearman SI; Franklin WA; Archer PG; Curiel T; Bitter M; Claman HN; Stemmer SM; Purdy M
J Clin Oncol; 1994 Jan; 12(1):28-36. PubMed ID: 7505806
[TBL] [Abstract][Full Text] [Related]
13. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
14. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
[TBL] [Abstract][Full Text] [Related]
15. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest.
Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD
J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200
[TBL] [Abstract][Full Text] [Related]
16. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
[TBL] [Abstract][Full Text] [Related]
17. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI
Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.
Fields KK; Elfenbein GJ; Trudeau WL; Perkins JB; Janssen WE; Moscinski LC
J Clin Oncol; 1996 Jun; 14(6):1868-76. PubMed ID: 8656255
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
[TBL] [Abstract][Full Text] [Related]
20. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
